Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza (Q30407794)

21 June 2017

1 reference

title

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza (English)

1 reference

21 June 2017

Hideyuki Ikematsu

1

1 reference

PubMed ID

21973296

21 June 2017

Naoki Kawai

series ordinal

2

1 reference

21 June 2017

1 October 2011

1 reference

Expert Review of Anti-infective Therapy

21 June 2017

1 reference

21 June 2017

9

1 reference

21 June 2017

851-857

1 reference

21 June 2017

10

1 reference

The impact of influenza on the health and health care utilisation of elderly people.

21 June 2017

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

[Estimation of excess mortality associated with influenza epidemics specific for sex, age and cause of death in Japan during 1987-2005].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Encephalitis and encephalopathy associated with an influenza epidemic in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.112

21 January 2018

Identifiers

DOI

10.1586/ERI.11.112

1 reference

21 June 2017

1 reference

PubMed ID

21973296